Skip to main content
Clinical Trials/NCT03575663
NCT03575663
Completed
Not Applicable

Bronchial Challenge Testing in Asthma: The Effect of Mannitol Dry Powder Inhalation on Volatile Organic Compounds in Exhaled Breath

University of East Anglia1 site in 1 country46 target enrollmentApril 25, 2018
ConditionsAsthma

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Asthma
Sponsor
University of East Anglia
Enrollment
46
Locations
1
Primary Endpoint
Changes in exhaled breath profile
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

This is a randomised, controlled, cross-over study to determine the effect of indirect bronchial challenge testing upon volatile organic compounds (VOCs) in the exhaled breath of adults with well-controlled, mild-to-moderate asthma.

Participants will undergo baseline evaluation including clinical history, spirometry, exhaled nitric oxide measurement (FeNO), phlebotomy (blood eosinophil count), and sampling of exhaled breath VOCs. Participants will be randomised to receive either an indirect bronchial challenge test using mannitol dry powder (MDP) or a sham bronchial challenge, followed by further sampling of breath VOCs. The study will consist of a consent visit and two assessment visits with participants allocated to receive one of the two challenges (MDP or sham) at each assessment. Data will be analysed to determine the effect of bronchial challenge upon exhaled breath VOC profiles.

Registry
clinicaltrials.gov
Start Date
April 25, 2018
End Date
February 28, 2019
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male or female
  • Aged 18 or over
  • Able to provide informed consent
  • Self-report of asthma diagnosis from health professional
  • Diagnostic confirmation meeting British Thoracic Society guidelines will be sought from primary care
  • Non-smokers; or ex-smokers of at least two years duration with less than a ten pack year history
  • Asthma Control Questionnaire score \< 1.0
  • Asthma treated according to level-1 to level-2 of British Thoracic Society treatment guidelines

Exclusion Criteria

  • Respiratory tract infection, asthma exacerbation or change in treatment step within the previous four weeks
  • Major chronic cardiorespiratory disease other than asthma
  • Significant comorbid condition
  • Condition that may be compromised by repeated spirometry manoeuvres or induced bronchospasm
  • Asthma Control Questionnaire score \>1.0
  • Asthma treated at level 3 of the treatment guidelines or higher
  • Pregnant or nursing mothers
  • Current smokers or 'vapers'
  • Ex-smokers of \< 2 years duration or \> 10 pack years.
  • Participating in a clinical trial of an investigational medicinal product (CTIMP).

Outcomes

Primary Outcomes

Changes in exhaled breath profile

Time Frame: Immediately post-bronchial challenge

Exhaled volatile organic compounds (VOCs) will be captured on sorbent material and analysed by gas chromatography-mass spectrometry. Post-bronchial challenge samples will be compared with baseline, pre-challenge samples. Differences in exhaled VOC profile will be assessed for significance.

Study Sites (1)

Loading locations...

Similar Trials